QED is very pleased to be starting work on a large phase III Osteoporsis trial being conducted in multiple countries including Eastern Europe and South Africa. The study, which was contracted to QED in the latter part of 2008, is a key project for its Biotech Sponsor and will serve as the pivotal efficacy trial for regulatory authorities.
Osteoporosis is a common disease characterised by the loss of bone mass (thinning of bones) that leads to an increase in bone fragility and heightened risk of fractures, especially at the hip, spine and wrist.
Thomas Ogorka, QED’s CEO said “We are delighted to be able to assist this Sponsor with development of a treatment, to address a painful and debilitating disease, with what appears to be considerable advantage of easier administration.”
QED’s involvement in the study is currently anticpated to last into 2011.